24 results on '"Bourboulia, Dimitra"'
Search Results
2. The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect
- Author
-
Woodford, Mark R., Baker-Williams, Alexander J., Sager, Rebecca A., Backe, Sarah J., Blanden, Adam R., Hashmi, Fiza, Kancherla, Priyanka, Gori, Alessandro, Loiselle, David R., Castelli, Matteo, Serapian, Stefano A., Colombo, Giorgio, Haystead, Timothy A., Jensen, Sandra M., Stetler-Stevenson, William G., Loh, Stewart N., Schmidt, Laura S., Linehan, W. Marston, Bah, Alaji, Bourboulia, Dimitra, Bratslavsky, Gennady, and Mollapour, Mehdi
- Abstract
Aerobic glycolysis in cancer cells, also known as the ‘Warburg effect’, is driven by hyperactivity of lactate dehydrogenase A (LDHA). LDHA is thought to be a substrate-regulated enzyme, but it is unclear whether a dedicated intracellular protein also regulates its activity. Here, we identify the human tumor suppressor folliculin (FLCN) as a binding partner and uncompetitive inhibitor of LDHA. A flexible loop within the amino terminus of FLCN controls movement of the LDHA active-site loop, tightly regulating its enzyme activity and, consequently, metabolic homeostasis in normal cells. Cancer cells that experience the Warburg effect show FLCN dissociation from LDHA. Treatment of these cells with a decapeptide derived from the FLCN loop region causes cell death. Our data suggest that the glycolytic shift of cancer cells is the result of FLCN inactivation or dissociation from LDHA. Together, FLCN-mediated inhibition of LDHA provides a new paradigm for the regulation of glycolysis.
- Published
- 2021
- Full Text
- View/download PDF
3. Activation of autophagy depends on Atg1/Ulk1-mediated phosphorylation and inhibition of the Hsp90 chaperone machinery
- Author
-
Backe, Sarah J., Sager, Rebecca A., Heritz, Jennifer A., Wengert, Laura A., Meluni, Katherine A., Aran-Guiu, Xavier, Panaretou, Barry, Woodford, Mark R., Prodromou, Chrisostomos, Bourboulia, Dimitra, and Mollapour, Mehdi
- Published
- 2024
- Full Text
- View/download PDF
4. Protocol to characterize extracellular c-Src tyrosine kinase function through substrate interaction and phosphorylation
- Author
-
Omini, Michael P., Alsalih, Deema, Votra, SarahBeth D., and Bourboulia, Dimitra
- Abstract
Cellular Src tyrosine kinase (c-Src) exists in the secretomes of several human cancers (extracellular, e-Src). Phosphoproteomics has demonstrated the existence of 114 potential extracellular e-Src substrates in addition to Tissue Inhibitor of Metalloproteinases 2. Here, we present a protocol to characterize secreted tyrosine-phosphorylated substrates as a result of c-Src expression and secretion. We describe steps for collecting cell secretomes and extracts, performing antibody treatment and Ni-NTA pull-down, and detecting protein-protein interaction and substrate Y-phosphorylation. This protocol is adaptable for studies examining the function of other extracellular kinases.
- Published
- 2023
- Full Text
- View/download PDF
5. Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer
- Author
-
Dushukyan, Natela, Dunn, Diana M., Sager, Rebecca A., Woodford, Mark R., Loiselle, David R., Daneshvar, Michael, Baker-Williams, Alexander J., Chisholm, John D., Truman, Andrew W., Vaughan, Cara K., Haystead, Timothy A., Bratslavsky, Gennady, Bourboulia, Dimitra, and Mollapour, Mehdi
- Abstract
The serine/threonine protein phosphatase 5 (PP5) regulates multiple cellular signaling networks. A number of cellular factors, including heat shock protein 90 (Hsp90), promote the activation of PP5. However, it is unclear whether post-translational modifications also influence PP5 phosphatase activity. Here, we show an “on/off switch” mechanism for PP5 regulation. The casein kinase 1δ (CK1δ) phosphorylates T362 in the catalytic domain of PP5, which activates and enhances phosphatase activity independent of Hsp90. Overexpression of the phosphomimetic T362E-PP5 mutant hyper-dephosphorylates substrates such as the co-chaperone Cdc37 and glucocorticoid receptor in cells. Our proteomic approach revealed that the tumor suppressor von Hippel-Lindau protein (VHL) interacts with and ubiquitinates K185/K199-PP5 for proteasomal degradation in a hypoxia- and prolyl-hydroxylation-independent manner. Finally, VHL-deficient clear cell renal cell carcinoma (ccRCC) cell lines and patient tumors exhibit elevated PP5 levels. Downregulation of PP5 causes ccRCC cells to undergo apoptosis, suggesting a prosurvival role for PP5 in kidney cancer.
- Published
- 2017
- Full Text
- View/download PDF
6. PhosY-secretome profiling combined with kinase-substrate interaction screening defines active c-Src-driven extracellular signaling
- Author
-
Backe, Sarah J., Votra, SarahBeth D., Stokes, Matthew P., Sebestyén, Endre, Castelli, Matteo, Torielli, Luca, Colombo, Giorgio, Woodford, Mark R., Mollapour, Mehdi, and Bourboulia, Dimitra
- Abstract
c-Src tyrosine kinase is a renowned key intracellular signaling molecule and a potential target for cancer therapy. Secreted c-Src is a recent observation, but how it contributes to extracellular phosphorylation remains elusive. Using a series of domain deletion mutants, we show that the N-proximal region of c-Src is essential for its secretion. The tissue inhibitor of metalloproteinases 2 (TIMP2) is an extracellular substrate of c-Src. Limited proteolysis-coupled mass spectrometry and mutagenesis studies verify that the Src homology 3 (SH3) domain of c-Src and the P31VHP34motif of TIMP2 are critical for their interaction. Comparative phosphoproteomic analyses identify an enrichment of PxxP motifs in phosY-containing secretomes from c-Src-expressing cells with cancer-promoting roles. Inhibition of extracellular c-Src using custom SH3-targeting antibodies disrupt kinase-substrate complexes and inhibit cancer cell proliferation. These findings point toward an intricate role for c-Src in generating phosphosecretomes, which will likely influence cell-cell communication, particularly in c-Src-overexpressing cancers.
- Published
- 2023
- Full Text
- View/download PDF
7. Activation of autophagy depends on Atg1/Ulk1-mediated phosphorylation and inhibition of the Hsp90 chaperone machinery
- Author
-
Backe, Sarah J., Sager, Rebecca A., Heritz, Jennifer A., Wengert, Laura A., Meluni, Katherine A., Aran-Guiu, Xavier, Panaretou, Barry, Woodford, Mark R., Prodromou, Chrisostomos, Bourboulia, Dimitra, and Mollapour, Mehdi
- Abstract
Cellular homeostasis relies on both the chaperoning of proteins and the intracellular degradation system that delivers cytoplasmic constituents to the lysosome, a process known as autophagy. The crosstalk between these processes and their underlying regulatory mechanisms is poorly understood. Here, we show that the molecular chaperone heat shock protein 90 (Hsp90) forms a complex with the autophagy-initiating kinase Atg1 (yeast)/Ulk1 (mammalian), which suppresses its kinase activity. Conversely, environmental cues lead to Atg1/Ulk1-mediated phosphorylation of a conserved serine in the amino domain of Hsp90, inhibiting its ATPase activity and altering the chaperone dynamics. These events impact a conformotypic peptide adjacent to the activation and catalytic loop of Atg1/Ulk1. Finally, Atg1/Ulk1-mediated phosphorylation of Hsp90 leads to dissociation of the Hsp90:Atg1/Ulk1 complex and activation of Atg1/Ulk1, which is essential for initiation of autophagy. Our work indicates a reciprocal regulatory mechanism between the chaperone Hsp90 and the autophagy kinase Atg1/Ulk1 and consequent maintenance of cellular proteostasis.
- Published
- 2023
- Full Text
- View/download PDF
8. Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors
- Author
-
Woodford, Mark R., Truman, Andrew W., Dunn, Diana M., Jensen, Sandra M., Cotran, Richard, Bullard, Renee, Abouelleil, Mourad, Beebe, Kristin, Wolfgeher, Donald, Wierzbicki, Sara, Post, Dawn E., Caza, Tiffany, Tsutsumi, Shinji, Panaretou, Barry, Kron, Stephen J., Trepel, Jane B., Landas, Steve, Prodromou, Chrisostomos, Shapiro, Oleg, Stetler-Stevenson, William G., Bourboulia, Dimitra, Neckers, Len, Bratslavsky, Gennady, and Mollapour, Mehdi
- Abstract
The molecular chaperone Hsp90 protects deregulated signaling proteins that are vital for tumor growth and survival. Tumors generally display sensitivity and selectivity toward Hsp90 inhibitors; however, the molecular mechanism underlying this phenotype remains undefined. We report that the mitotic checkpoint kinase Mps1 phosphorylates a conserved threonine residue in the amino-domain of Hsp90. This, in turn, regulates chaperone function by reducing Hsp90 ATPase activity while fostering Hsp90 association with kinase clients, including Mps1. Phosphorylation of Hsp90 is also essential for the mitotic checkpoint because it confers Mps1 stability and activity. We identified Cdc14 as the phosphatase that dephosphorylates Hsp90 and disrupts its interaction with Mps1. This causes Mps1 degradation, thus providing a mechanism for its inactivation. Finally, Hsp90 phosphorylation sensitizes cells to its inhibitors, and elevated Mps1 levels confer renal cell carcinoma selectivity to Hsp90 drugs. Mps1 expression level can potentially serve as a predictive indicator of tumor response to Hsp90 inhibitors.
- Published
- 2016
- Full Text
- View/download PDF
9. A specialized Hsp90 co-chaperone network regulates steroid hormone receptor response to ligand
- Author
-
Backe, Sarah J., Sager, Rebecca A., Regan, Bethany R., Sit, Julian, Major, Lauren A., Bratslavsky, Gennady, Woodford, Mark R., Bourboulia, Dimitra, and Mollapour, Mehdi
- Abstract
Heat shock protein-90 (Hsp90) chaperone machinery is involved in the stability and activity of its client proteins. The chaperone function of Hsp90 is regulated by co-chaperones and post-translational modifications. Although structural evidence exists for Hsp90 interaction with clients, our understanding of the impact of Hsp90 chaperone function toward client activity in cells remains elusive. Here, we dissect the impact of recently identified higher eukaryotic co-chaperones, FNIP1/2 (FNIPs) and Tsc1, toward Hsp90 client activity. Our data show that Tsc1 and FNIP2 form mutually exclusive complexes with FNIP1, and that unlike Tsc1, FNIP1/2 interact with the catalytic residue of Hsp90. Functionally, these co-chaperone complexes increase the affinity of the steroid hormone receptors glucocorticoid receptor and estrogen receptor to their ligands in vivo. We provide a model for the responsiveness of the steroid hormone receptor activation upon ligand binding as a consequence of their association with specific Hsp90:co-chaperone subpopulations.
- Published
- 2022
- Full Text
- View/download PDF
10. c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells
- Author
-
Dunn, Diana M., Woodford, Mark R., Truman, Andrew W., Jensen, Sandra M., Schulman, Jacqualyn, Caza, Tiffany, Remillard, Taylor C., Loiselle, David, Wolfgeher, Donald, Blagg, Brian S.J., Franco, Lucas, Haystead, Timothy A., Daturpalli, Soumya, Mayer, Matthias P., Trepel, Jane B., Morgan, Rhodri M.L., Prodromou, Chrisostomos, Kron, Stephen J., Panaretou, Barry, Stetler-Stevenson, William G., Landas, Steve K., Neckers, Len, Bratslavsky, Gennady, Bourboulia, Dimitra, and Mollapour, Mehdi
- Abstract
The ability of Heat Shock Protein 90 (Hsp90) to hydrolyze ATP is essential for its chaperone function. The co-chaperone Aha1 stimulates Hsp90 ATPase activity, tailoring the chaperone function to specific “client” proteins. The intracellular signaling mechanisms directly regulating Aha1 association with Hsp90 remain unknown. Here, we show that c-Abl kinase phosphorylates Y223 in human Aha1 (hAha1), promoting its interaction with Hsp90. This, consequently, results in an increased Hsp90 ATPase activity, enhances Hsp90 interaction with kinase clients, and compromises the chaperoning of non-kinase clients such as glucocorticoid receptor and CFTR. Suggesting a regulatory paradigm, we also find that Y223 phosphorylation leads to ubiquitination and degradation of hAha1 in the proteasome. Finally, pharmacologic inhibition of c-Abl prevents hAha1 interaction with Hsp90, thereby hypersensitizing cancer cells to Hsp90 inhibitors both in vitro and ex vivo.
- Published
- 2015
- Full Text
- View/download PDF
11. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells
- Author
-
Iwai, Aki, Bourboulia, Dimitra, Mollapour, Mehdi, Jensen-Taubman, Sandra, Lee, Sunmin, Donnelly, Alison C., Yoshida, Soichiro, Miyajima, Naoto, Tsutsumi, Shinji, Smith, Armine K., Sun, David, Wu, Xiaolin, Blagg, Brian S., Trepel, Jane B., Stetler-Stevenson, William G., and Neckers, Len
- Abstract
Heat shock protein 90 (Hsp90) is an essential, evolutionarily conserved molecular chaperone. Cancer cells rely on Hsp90 to chaperone mutated and/or activated oncoproteins, and its involvement in numerous signaling pathways makes it an attractive target for drug development. Surprisingly, however, the impact of Hsp90 inhibitors on cancer cells is frequently cytostatic in nature, and efforts to enhance the antitumor activity of Hsp90 inhibitors in the clinic remain a significant challenge. In agreement with previous data obtained using Wee1 siRNA, we show that dual pharmacologic inhibition of Wee1 tyrosine kinase and Hsp90 causes cancer cells to undergo apoptosis in vitro and in vivo. Gene expression profiling revealed that induction of the intrinsic apoptotic pathway by this drug combination coincided with transcriptional downregulation of Survivin and Wee1, an outcome not seen in cells treated separately with either agent. At the translational level, expression of these two proteins, as well as activated Akt, was completely abrogated. These data support the hypothesis that Wee1 inhibition sensitizes cancer cells to Hsp90 inhibitors; they establish combined Wee1/Hsp90 inhibition as a novel therapeutic strategy; and they provide a mechanistic rationale for enhancing the pro-apoptotic activity of Hsp90 inhibitors.
- Published
- 2012
- Full Text
- View/download PDF
12. Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
- Author
-
G. Stetler-Stevenson, William, Bourboulia, Dimitra, Guedez, Liliana, and Jensen-Taubman, Sandra
- Abstract
Dr. Judah Folkman first introduced the concept of anti-angiogenic therapy almost four decades ago. This novel idea has subsequently been supported by extensive research in the multistep process of tumor-associated angiogenesis. As new blood vessels are formed, angiogenesis is switched on within the tumor microenvironment and the physiological balance between endogenous pro-angiogenic and anti-angiogenic factors is disrupted. Since then, angiogenesis inhibitors have been developed as drugs and administered in the clinic as part of anti-cancer therapy. Tissue inhibitor of metalloproteinase 2 (TIMP-2) is an endogenous inhibitor of angiogenesis that was initially discovered through the ability to inhibit matrix metalloproteinase (MMP) activity. Subsequently, TIMP-2 was shown to suppress endothelial cell proliferation and migration through MMP dependent and independent mechanisms. Moreover, recent studies indicate that TIMP-2- mediated inhibition of tumor growth may occur, at least in part, via mechanisms that are distinct from its ability to inhibit MMP activity. TIMP-2 is an essential element of the normal tissue microenvironment in the presence of low levels of MMP expression. However, in tumor tissue TIMP-2 levels are reduced. Recent experiments demonstrate that reconstitution of TIMP-2 expression in tumors not only inhibits tumor angiogenesis, but also acts directly on tumor cells to modulate interactions between the tumor cells and the microenvironment. These recent research findings support the idea that TIMP-2 is an excellent candidate for preclinical development as a novel biological agent for cancer therapy.
- Published
- 2012
13. Endogenous Angiogenesis Inhibitor Blocks Tumor Growth via Direct and Indirect Effects on Tumor Microenvironment
- Author
-
Bourboulia, Dimitra, Jensen-Taubman, Sandra, Rittler, Matthew R., Han, Hui Ying, Chatterjee, Tania, Wei, Beiyang, and Stetler-Stevenson, William G.
- Abstract
Tissue inhibitor of matrix metalloproteinase–2 (TIMP-2) belongs to a small family of endogenous proteins that inhibits a group of enzymes, the matrix metalloproteinases (MMPs). TIMP-2 inhibits endothelial cell proliferation and migration in vitroand angiogenesis in vivo, through MMP-dependent and -independent mechanisms. However, little is known regarding the contribution of these mechanisms to the antitumor effects of TIMP-2. Using a retroviral delivery system, we stably overexpressed TIMP-2 and its mutant Ala+TIMP-2 (devoid of MMP inhibitory activity) in human adenocarcinoma A549 cells. Using real time PCR, and enzyme-linked immunosorbent assay (ELISA), we confirmed enhanced TIMP-2 expression and its MMP inhibitory activity by reverse zymography. In vitro, growth assays suggested that TIMP-2 and Ala+TIMP-2 did not alter basal cell proliferation rates, however, tumor cell migration and invasion were inhibited. In vivo, both TIMP-2 and Ala+TIMP-2 A549 xenografts exhibited reduced growth rate, CD31 immunostaining indicated decreased intratumoral microvascular density, and TUNEL demonstrated enhanced tumor cell apoptosis. Immunoblotting and immunohistochemical analyses of A549 xenograft tissues with either phospho-FAK (Tyr397) or phospho-AKT (Ser473) showed decreased activation in both TIMP-2 and Ala+TIMP-2 tumor cells. We conclude that TIMP-2-mediated inhibition of tumor growth occurs, at least in part, independently of MMP inhibition, and is a consequence of both direct effects of TIMP-2 on tumor cells and modulation of the tumor microenvironment.
- Published
- 2011
- Full Text
- View/download PDF
14. Risk factors for Kaposi's sarcoma: A case-control study of HIV-seronegative people in Uganda
- Author
-
Ziegler, John, Newton, Robert, Bourboulia, Dimitra, Casabonne, Delphine, Beral, Valerie, Mbidde, Edward, Carpenter, Lucy, Reeves, Gillian, Parkin, D. Maxwell, Wabinga, Henry, Mbulaiteye, Sam, Jaffe, Harold, Weiss, Robin, and Boshoff, Chris
- Abstract
As part of a larger investigation of cancer in Uganda, we conducted a case-control study of Kaposi's sarcoma in human immunodeficiency virus-1 (HIV)-seronegative adults presenting at hospitals in Kampala. Cases comprised 117 HIV-seronegative patients with Kaposi's sarcoma and controls comprised 1,282 HIV-seronegative patients with a provisional diagnosis of cancer other than Kaposi's sarcoma. Study participants were interviewed about social and lifestyle factors, tested for HIV and, if there was sufficient sera, for antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV or human herpesvirus 8 [HHV8]), using an immunofluorescent assay. Independent effects of these factors were identified using unconditional logistic regression, after adjusting for age group (<30, 3044, 45+) and sex. Antibody status for KSHV was available for 68% (80) of cases and for 45% (607) of controls. Among cases, 78% (91) were male and 57% (66) were over the age of 35. Cases were more likely than controls to be from tribal groups other than the Baganda (p = 0.05), to have higher household incomes (p = 0.003), to have left their home region at younger ages (p < 0.001), to own goats or pigs (p = 0.02) and to rarely or never use shoes (p < 0.001). Similar results were obtained when analyses were restricted to cases and controls with anti-KSHV antibodies. The seroprevalence of KSHV was 79% (63/80) in those with Kaposi's sarcoma as compared to 50% (302/607) in those without (χ2 heterogeneity (1 df) = 21.0; p < 0.001) and the risk of the tumour increased with increasing anti-KSHV antibody titres (χ2 trend (1 df) = 29.7; p < 0.001). The risk of Kaposi's sarcoma is clearly linked to antibody status for KSHV, but it would seem that in Uganda other factors are also important in the development of the tumour. © 2002 Wiley-Liss, Inc.
- Published
- 2003
- Full Text
- View/download PDF
15. The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda
- Author
-
Newton, Robert, Ziegler, John, Bourboulia, Dimitra, Casabonne, Delphine, Beral, Valerie, Mbidde, Edward, Carpenter, Lucy, Reeves, Gillian, Parkin, D. Maxwell, Wabinga, Henry, Mbulaiteye, Sam, Jaffe, Harold, Weiss, Robin, and Boshoff, Chris
- Abstract
The association between the prevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV or human herpesvirus 8 [HHV-8]) and sociodemographic, sexual, reproductive and lifestyle factors was investigated in a study of adults presenting with cancer at hospitals in Kampala, Uganda. Patients were interviewed and tested for antibodies against KSHV (using an indirect immunofluorescent assay). Data are presented for 607 patients who were not infected with the human immunodeficiency virus-1 (HIV) and who did not have Kaposi's sarcoma (these included people with cancers of the uterine cervix [140], breast [58], liver [41], oesophagus [36], lymphoma [47], other cancers [285] and benign tumours [63]). The prevalence of anti-KSHV antibodies was 50% overall (302/607) and did not differ significantly by cancer site (p = 0.4) or sex (p = 0.2), but increased linearly with age from 35% in those under 25 years to 55% in those 45 years and over (χ2 trend [1 df] = 9.1; p < 0.001). After adjusting for age and sex, anti-KSHV antibodies were more common in tribal groups other than the Baganda tribe (54% vs. 45% among Baganda; p = 0.02), but there was no significant (p > 0.05) variation in seroprevalence by district of birth, region of residence prior to becoming ill or various measures of wealth. The prevalence of anti-KSHV antibodies decreased with increasing number of older siblings, although this may be due to chance (p = 0.05) and was higher among people who had ever been married (p = 0.03). There was no significant association (p > 0.05) between the presence of antibodies against KSHV and other sexual and reproductive factors. Among the 302 patients with anti-KSHV antibodies, the proportion with high titres increased linearly with increasing age (p = 0.03) and was higher among those reporting having had a blood transfusion (p = 0.03). In conclusion, in this population in Uganda, where KSHV is relatively common, the prevalence of anti-KSHV antibodies increased with age but showed little association with nearly 50 other factors studied. © 2002 Wiley-Liss, Inc.
- Published
- 2003
- Full Text
- View/download PDF
16. Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy
- Author
-
Wilkinson, John, Cope, Alethea, Gill, Jas, Bourboulia, Dimitra, Hayes, Peter, Imami, Nesrina, Kubo, Toru, Marcelin, Anne, Calvez, Vincent, Weiss, Robin, Gazzard, Brian, Boshoff, Chris, and Gotch, Frances
- Abstract
ABSTRACTFollowing the introduction of highly active antiretroviral therapy (HAART), the incidence of Kaposi's sarcoma (KS) has significantly declined in human immunodeficiency virus type 1 (HIV-1)-positive (HIV-1+) individuals and clinical remission is often observed. We hypothesize that these effects are partly due to anti-KS-associated herpesvirus (KSHV) immune restoration. Here, 15-mer overlapping peptides from proteins K12 and K8.1 were used to identify novel KSHV-specific cytotoxic T-lymphocyte epitopes. Three immunogenic peptides, two lytic and one latent, were subsequently used to monitor the anti-KSHV CD8+T-cell responses in a cohort of 19 HIV-1+KSHV+/-KS+/-individuals during 52 weeks of HAART. KSHV and HIV-1 loads, KSHV antibody titers, and both CD4+and CD8+T-lymphocyte counts were enumerated. Prior to HAART, the total number of spot-forming cells (SFC) for all three peptides correlated with both CD4+and CD8+T-lymphocyte counts (P= 0.05) in the KSHV-positive KS-positive cohort (n= 11). Following 52 weeks of HAART, significant decreases in HIV-1 and KSHV loads were associated with significant increases in CD4+T-lymphocyte counts and number of SFC for the three KSHV-specific peptides. Although these increases were modest in comparison to the number of SFC observed with the HIV-1 gagpeptide SLYNTVATL, they represented a fourfold increase from the baseline, continuing an upward trend to week 52.
- Published
- 2002
- Full Text
- View/download PDF
17. Characterization of Monoclonal Antibodies Raised against the Latent Nuclear Antigen of Human Herpesvirus 8
- Author
-
Kellam, Paul, Bourboulia, Dimitra, Dupin, Nicolas, Shotton, Chris, Fisher, Cyril, Talbot, Simon, Boshoff, Chris, and Weiss, Robin A.
- Abstract
ABSTRACTHuman herpesvirus 8 (HHV-8; also designated Kaposi’s sarcoma-associated herpesvirus) is the likely etiological agent of Kaposi’s sarcoma (KS). HHV-8 encodes a latent nuclear antigen (LNA) which is the product of the viral gene orf 73. LNA is recognized by most infected patient sera and is the basis of current immunofluorescence assays used in epidemiological studies of HHV-8 infection. Here we describe the characterization of four monoclonal antibodies raised to the C-terminal third of LNA–glutathioneS-transferase fusion proteins. These monoclonal antibodies recognized discrete linear epitopes within the C terminus and repetitive region of LNA, detected antigen in primary effusion lymphoma (PEL) cells, and precipitated a 220- to 230-kDa protein doublet corresponding to LNA from HHV-8-infected PEL cell lines. In situ immunocytochemistry of KS lesions with these antibodies show that LNA is extensively expressed in KS spindle cells.
- Published
- 1999
- Full Text
- View/download PDF
18. Lack of serologic association of human herpesvirus-8 (KSHV) in patients with monoclonal gammopathy of undetermined significance with and without progression to multiple myeloma
- Author
-
Ablashi, Dharam V., Chatlynne, Louise, Thomas, David, Bourboulia, Dimitra, Rettig, Matthew B., Vescio, Robert A., Viza, Dimitri, Gill, Parkash, Kyle, Robert A., Berenson, James R., and Whitman, James E.
- Abstract
Because human herpesvirus-8 (HHV-8) DNA has been found in multiple myeloma (MM) patients by polymerase chain reaction, it was suggested that HHV-8 may play a role in the transformation of monoclonal gammopathy of undetermined significance (MGUS) to MM. Therefore, 362 MGUS sera with and without progression to MM were tested for IgG antibody to HHV-8. Only 7.8% of the MGUS sera contained HHV-8 antibody to lytic proteins, and IgG antibody to HHV-8 latent antigen was even lower than lytic antibody (2.9%). No differences were observed in the distribution of antibody to HHV-8 in sera from MGUS patients who progressed to MM. The seroprevalences of HHV-8 in MGUS (7.8%), MM (5.4%), and healthy donors (5.9%) were similar, thus arguing for the lack of epidemiologic evidence of HHV-8 participation in the pathogenesis of MM. MGUS patients were immune competent in response to Epstein-Barr virus (EBV) infection because 97% contained antibody to EBV virus capsid antigen.
- Published
- 2000
- Full Text
- View/download PDF
19. Lack of serologic association of human herpesvirus-8 (KSHV) in patients with monoclonal gammopathy of undetermined significance with and without progression to multiple myeloma
- Author
-
Ablashi, Dharam V., Chatlynne, Louise, Thomas, David, Bourboulia, Dimitra, Rettig, Matthew B., Vescio, Robert A., Viza, Dimitri, Gill, Parkash, Kyle, Robert A., Berenson, James R., and Whitman, James E.
- Abstract
Because human herpesvirus-8 (HHV-8) DNA has been found in multiple myeloma (MM) patients by polymerase chain reaction, it was suggested that HHV-8 may play a role in the transformation of monoclonal gammopathy of undetermined significance (MGUS) to MM. Therefore, 362 MGUS sera with and without progression to MM were tested for IgG antibody to HHV-8. Only 7.8% of the MGUS sera contained HHV-8 antibody to lytic proteins, and IgG antibody to HHV-8 latent antigen was even lower than lytic antibody (2.9%). No differences were observed in the distribution of antibody to HHV-8 in sera from MGUS patients who progressed to MM. The seroprevalences of HHV-8 in MGUS (7.8%), MM (5.4%), and healthy donors (5.9%) were similar, thus arguing for the lack of epidemiologic evidence of HHV-8 participation in the pathogenesis of MM. MGUS patients were immune competent in response to Epstein-Barr virus (EBV) infection because 97% contained antibody to EBV virus capsid antigen.
- Published
- 2000
- Full Text
- View/download PDF
20. PD46-11 PHOSPHORYLATION AND UBIQUITINATION REGULATE PROTEIN PHOSPHATASE-5 ACTIVITY AND ITS PROSURVIVAL ROLE IN KIDNEY CANCER.
- Author
-
Dushukyan, Natela, Daneshvar, Michael, Sager, Rebecca, Woodford, Mark, Baker-Williams, Alexander, Chisholm, John, Loiselle, David, Truman, Andrew, Haystead, Timothy, Shapiro, Oleg, Bourboulia, Dimitra, Bratslavsky, Gennady, and Mollapour, Mehdi
- Subjects
PHOSPHATASE regulation ,UBIQUITINATION ,RENAL cancer - Published
- 2018
- Full Text
- View/download PDF
21. MP88-13 TUMOR SUPPRESSOR TSC1 IS A NEW HSP90 COCHAPERONE THAT FACILITATES FOLDING OF KINASE AND NON-KINASE CLIENTS.
- Author
-
Woodford, Mark, Sager, Rebecca, Blanden, Adam, Loh, Stewart, Gutmann, David, Shapiro, Oleg, Bourboulia, Dimitra, Wong, Michael, Bratslavsky, Gennady, and Mollapour, Mehdi
- Subjects
TUMOR suppressor genes ,GENETIC mutation ,KINASES - Published
- 2018
- Full Text
- View/download PDF
22. Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90
- Author
-
Sager, Rebecca A., Woodford, Mark R., Backe, Sarah J., Makedon, Alan M., Baker-Williams, Alexander J., DiGregorio, Bryanna T., Loiselle, David R., Haystead, Timothy A., Zachara, Natasha E., Prodromou, Chrisostomos, Bourboulia, Dimitra, Schmidt, Laura S., Linehan, W. Marston, Bratslavsky, Gennady, and Mollapour, Mehdi
- Abstract
The molecular chaperone Hsp90 stabilizes and activates client proteins. Co-chaperones and post-translational modifications tightly regulate Hsp90 function and consequently lead to activation of clients. However, it is unclear whether this process occurs abruptly or gradually in the cellular context. We show that casein kinase-2 phosphorylation of the co-chaperone folliculin-interacting protein 1 (FNIP1) on priming serine-938 and subsequent relay phosphorylation on serine-939, 941, 946, and 948 promotes its gradual interaction with Hsp90. This leads to incremental inhibition of Hsp90 ATPase activity and gradual activation of both kinase and non-kinase clients. We further demonstrate that serine/threonine protein phosphatase 5 (PP5) dephosphorylates FNIP1, allowing the addition of O-GlcNAc (O-linked N-acetylglucosamine) to the priming serine-938. This process antagonizes phosphorylation of FNIP1, preventing its interaction with Hsp90, and consequently promotes FNIP1 lysine-1119 ubiquitination and proteasomal degradation. These findings provide a mechanism for gradual activation of the client proteins through intricate crosstalk of post-translational modifications of the co-chaperone FNIP1.
- Published
- 2019
- Full Text
- View/download PDF
23. MP85-13 FNIP CO-CHAPERONES PROTECT THE TUMOR SUPPRESSOR FLCN FROM UBIQUITINATION AND DEGRADATION IN THE PROTEASOME.
- Author
-
Woodford, Mark, Dunn, Diana, Blanden, Adam, Loh, Stewart, Bourboulia, Dimitra, Schmidt, Laura, Linehan, W. Marston, Bratslavsky, Gennady, and Mollapour, Mehdi
- Subjects
MOLECULAR chaperones ,TUMOR suppressor genes ,UBIQUITINATION ,PROTEASOMES ,BIRT-Hogg-Dube syndrome ,KIDNEY tumors - Published
- 2016
- Full Text
- View/download PDF
24. MP39-02 OVEREXPRESSION OF MPS1 IN CLEAR CELL RENAL CELL CARCINOMA (CCRCC) CONFERS TUMOR SELECTIVITY ON HEAT SHOCK PROTEIN-90 (HSP90) INHIBITORS.
- Author
-
Abouelleil, Mourad, Dunn, Diana, Woodford, Mark, Jensen, Sandra, Chehab, Mahmoud, Madala, Alosh, Caza, Tiffany, Landas, Steve, Stetler-Stevenson, William G., Neckers, Len, Bourboulia, Dimitra, Bratslavsky, Gennady, and Mollapour, Mehdi
- Subjects
RENAL cell carcinoma ,GENETIC overexpression ,HEAT shock proteins ,ANEUPLOIDY ,NEOPLASTIC cell transformation ,GENETIC mutation ,GENETICS - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.